Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Daiichi Sankyo and Merck voluntarily withdrew the U.S. Biologics License Application seeking accelerated approval for ifinatamab deruxtecan in extensive-stage small cell lung cancer after progression on platinum-based chemotherapy. The withdrawal, following discussions with regulators, delays or removes a potential near-term U.S. commercialization catalyst for the oncology asset.

Analysis

The direct revenue loss to MRK is likely immaterial relative to its broader oncology franchise, but the signaling effect matters: the withdrawal raises the probability that FDA is applying a higher evidentiary bar to single-arm accelerated-approval filings in relapsed SCLC, particularly where safety management and confirmatory-trial feasibility are central. For MRK, the market risk is not near-term EPS; it is incremental pipeline multiple compression as investors reassess whether external oncology business development can offset the post-2028 KEYTRUDA loss-of-exclusivity profile.

AMGN is a relative beneficiary because a delayed alternative preserves its commercial runway in later-line SCLC. Jazz Pharmaceuticals (JAZZ) also benefits at the margin through reduced competitive pressure on Zepzelca, although neither read-through is likely large enough alone to alter consensus earnings. The more important second-order effect is across the ADC complex: B7-H3 programs may face longer development timelines, higher randomized-trial costs, and lower probability-adjusted peak-sales assumptions if FDA feedback reflects class-relevant concerns rather than asset-specific data.

Over days, MRK’s reaction should be contained unless management discloses a broader development delay, impairment, or changed economics with Daiichi Sankyo. Over the next 1-3 months, the key catalyst is whether MRK/Daiichi define a viable randomized pathway and whether FDA commentary indicates a narrow filing issue versus inadequate benefit-risk. A prompt revised path with clear enrollment timelines would falsify the negative pipeline read-through; conversely, a discontinued program or materially delayed pivotal study would justify further reductions to probability-adjusted oncology value.

Contrarian view: a broad MRK selloff would likely be excessive. This asset was not a meaningful component of near-term consensus revenue, and withdrawal can be a capital-allocation positive if it prevents substantial commercial spend behind a marginal differentiated product. The cleaner expression is relative rather than outright bearish MRK: own the incumbent SCLC franchise beneficiary against MRK until regulatory clarity emerges.

Key Decisions for Investors

• Do not add an outright MRK short solely on this event; treat any >3-4% underperformance versus XLV in the next week without new pipeline disclosures as a potential mean-reversion opportunity, given limited near-term EPS exposure.
• Initiate a 1-3 month tactical pair: long AMGN / short MRK in equal beta-adjusted dollars. The thesis is preservation of Imdelltra's later-line SCLC runway versus a modest increase in MRK oncology-pipeline uncertainty; exit if MRK/Daiichi disclose a defined resubmission pathway or AMGN reports adverse uptake/safety trends.
• Reduce probability-weighted peak-sales assumptions for pre-pivotal B7-H3 ADC exposure by 10-20% pending clarification of FDA's objections; avoid applying this mechanically to all ADCs unless the feedback is shown to concern platform-level toxicity or endpoint standards.
• Set an event alert for MRK's next earnings call: a disclosed impairment, program discontinuation, or delay beyond a randomized confirmatory timeline is bearish for pipeline valuation; a stated pivotal design, enrollment start, and regulatory alignment would remove the relative-trade catalyst.